Umang Swami

2 months ago | urotoday.com | Umang Swami

Read the Full Video TranscriptAlicia Morgans: Hi. I'm so excited to be here today with Doctor Umang Swami, who is joining me from the University of Utah, where he is an assistant professor of oncology at the Huntsman Cancer Institute. Thank you so much for being here with me today. Umang Swami: Thank you, Dr. Morgans and UroToday for this opportunity to discuss our study. Alicia Morgans: Wonderful. So let's just make sure that everyone knows.

Jun 17, 2024 | bpno.dk | Umang Swami

juni 2024 Dr. Umang Swami from Huntsman Cancer Institute, University of Otah, presents in this MEDtalk a study that compared cabozantinib alone versus cabozantinib with immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma patients. The results showed no significant benefit from adding PD-1/PD-L1 inhibitors, suggesting that single-agent cabozantinib is sufficient and avoids extra toxicity.

Aug 16, 2023 | frontiersin.org | Sun Young |South Brisbane |Umang Swami |Fabio Calabro'

1 IntroductionKidney cancer is one of the most frequently diagnosed cancers in the United States, and the activity of traditional cytotoxic chemotherapy is limited in patients with metastatic renal cell carcinoma (RCC) (1). The phase 3 multicenter, open-label, randomized, CLEAR study (Study 307/KEYNOTE-581) compared the efficacy and safety of lenvatinib plus pembrolizumab or everolimus versus sunitinib as a first-line treatment for patients with advanced RCC (2).